Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

lesinurad Oral Tablet [Zurampic]

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Up to 90% of gout patients experience low uric acid (UA) excretion rather than high UA production. The selective UA reabsorption… Expand
Review
2017
Review
2017
  • E. Deeks
  • Drugs & Aging
  • 2017
  • Corpus ID: 3891146
Lesinurad (Zurampic®) is an oral selective inhibitor of the URAT1 and OAT4 uric acid (UA) transporters of the kidney, via which… Expand
  • table 1
  • figure 1
2016
2016
BackgroundExcess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Review
2016
Review
2016
Lesinurad (ZURAMPIC®) is an oral urate–anion exchanger transporter 1 (URAT1) inhibitor developed by Ardea Biosciences (a… Expand
2016
2016
BACKGROUND Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most… Expand